Protein Science, Vol 7, Issue 3 619-627, Copyright © 1998 by Cold Spring Harbor Laboratory Press

ARTICLE

Solution structure of Compstatin, a potent complement inhibitor

D. MORIKIS, N. ASSA-MUNT, A. SAHU and J. D. LAMBRIS
The Burnham Institute, 10901 North Torrey Pines Road, La Jolla, California 92037

The third component of complement, C3, plays a central role in activation of the classical, alternative, and lectin pathways of complement activation. Recently, we have identified a 13-residue cyclic peptide (named Compstatin) that specifically binds to C3 and inhibits complement activation. To investigate the topology and the contribution of each critical residue to the binding of Compstatin to C3, we have now determined the solution structure using 2D NMR techniques; we have also synthesized substitution analogues and used these to study the structure-function relationships involved. Finally, we have generated an ensemble of a family of solution structures of the peptide with a hybrid distance geometry-restrained simulated-annealing methodology, using distance, dihedral angle, and (3)J(NH-H{alpha})-coupling constant restraints. The Compstatin structure contained a type I {beta}-turn comprising the segment Gln(5)-Asp(6)-Trp(7)-Gly(8). Preference for packing of the hydrophobic side chains of Val(3), Val(4), and Trp(7) was observed. The generated structure was also analyzed for consistency using NMR parameters such as NOE connectivity patterns, (3)J(NH-H{alpha})-coupling constants, and chemical shifts. Analysis of Ala substitution analogues suggested that Val(3), Gln(5), Asp(6), Trp(7), and Gly(8) contribute significantly to the inhibitory activity of the peptide. Substitution of Gly(8) caused a 100-fold decrease in inhibitory potency. In contrast, substitution of Val(4), His(9), His(10), and Arg(11) resulted in minimal change in the activity. These findings indicate that specific side-chain interactions and the {beta}-turn are critical for preservation of the conformational stability of Compstatin and they might be significant for maintaining the functional activity of Compstatin.
CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				B. J. C. Janssen, E. F. Halff, J. D. Lambris, and P. Gros Structure of Compstatin in Complex with Complement Component C3c Reveals a New Mechanism of Complement Inhibition J. Biol. Chem., October 5, 2007; 282(40): 29241 - 29247. [Abstract] [Full Text] [PDF]

				M. Katragadda, D. Morikis, and J. D. Lambris Thermodynamic Studies on the Interaction of the Third Complement Component and Its Inhibitor, Compstatin J. Biol. Chem., December 31, 2004; 279(53): 54987 - 54995. [Abstract] [Full Text] [PDF]

				A. H. J. Kim, I. D. Dimitriou, M. C. H. Holland, D. Mastellos, Y. M. Mueller, J. D. Altman, J. D. Lambris, and P. D. Katsikis Complement C5a Receptor Is Essential for the Optimal Generation of Antiviral CD8+ T Cell Responses J. Immunol., August 15, 2004; 173(4): 2524 - 2529. [Abstract] [Full Text] [PDF]

				A. M. Soulika, D. Morikis, M.-R. Sarrias, M. Roy, L. A. Spruce, A. Sahu, and J. D. Lambris Studies of Structure-Activity Relations of Complement Inhibitor Compstatin J. Immunol., August 15, 2003; 171(4): 1881 - 1890. [Abstract] [Full Text] [PDF]

				T. E. Mollnes, O.-L. Brekke, M. Fung, H. Fure, D. Christiansen, G. Bergseth, V. Videm, K. T. Lappegard, J. Kohl, and J. D. Lambris Essential role of the C5a receptor in E coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation Blood, August 13, 2002; 100(5): 1869 - 1877. [Abstract] [Full Text] [PDF]

				D. Morikis, M. Roy, A. Sahu, A. Troganis, P. A. Jennings, G. C. Tsokos, and J. D. Lambris The Structural Basis of Compstatin Activity Examined by Structure-Function-based Design of Peptide Analogs and NMR J. Biol. Chem., April 19, 2002; 277(17): 14942 - 14953. [Abstract] [Full Text] [PDF]

				A. Sahu, A. M. Soulika, D. Morikis, L. Spruce, W. T. Moore, and J. D. Lambris Binding Kinetics, Structure-Activity Relationship, and Biotransformation of the Complement Inhibitor Compstatin J. Immunol., September 1, 2000; 165(5): 2491 - 2499. [Abstract] [Full Text] [PDF]

				A. Sandoval, R. Ai, J. M. Ostresh, and R. T. Ogata Distal Recognition Site for Classical Pathway Convertase Located in the C345C/Netrin Module of Complement Component C5 J. Immunol., July 15, 2000; 165(2): 1066 - 1073. [Abstract] [Full Text] [PDF]

				B. Nilsson, R. Larsson, J. Hong, G. Elgue, K. N. Ekdahl, A. Sahu, and J. D. Lambris Compstatin Inhibits Complement and Cellular Activation in Whole Blood in Two Models of Extracorporeal Circulation Blood, September 1, 1998; 92(5): 1661 - 1667. [Abstract] [Full Text] [PDF]